Navigation Links
New anticoagulant discovered based on the same used by malaria vectors to feed on

An international project lead by the Molecular and Cell Biology Institute of Porto University with the participation of researchers from IMIM (Hospital del Mar Medical Research Institute) has, for the first time ever, deciphered the mechanism by which a substance called anophelin binds to an enzyme (thrombin) involved in the process of blood coagulation. This discovery was published in the last issue of the PNAS journal and opens the door to, on the one hand, designing a new generation of anticoagulant drugs with a totally different functioning to current ones and, on the other hand, fighting against the spreading of malaria by designing inhibitors for this substance.

Anophelin is a substance playing a crucial role in the nutrition of a large number of parasites like malaria-carrying Anopheles mosquitoes or vampire bats. These animals need to feed on fresh blood and stop it from coagulating while they are eating. To make this possible, they use powerful inhibitors of the coagulation process mainly affecting thrombin. Researchers have discovered that "anophelin blocks thrombin in a new and different way than other substances: it's like a key fitting in a lock of a door, but in this case the key fits in the other side" explains Ricardo Gutirrez Gallego, a member of the IMIM Bioanalysis research group.

The project is based on two recent studies which led to the discovery of thrombin inhibitors presenting new structures. For the inhibitor produced by Anopheles mosquitoes (anophelin), it was seen that after binding to thrombin, proteins did not degrade, so a systematic study was launched for all coagulants in the several variants of the Anopheles mosquito. By using very powerful and sensitive analytical techniques it was possible to determine and monitor in real time the molecule interactions in both anophelin and thrombin, leading to a detailed characterization of their structure and interaction. Researchers also performed mutations on this protein, i.e. they changed the amino acid at each time, so as to discover the crucial components of the molecule when it interacted with thrombin.

Blood coagulation is a complex mechanism to prevent bleeding after an injury. However, in some cases, the formation of blood clots can lead to a myocardial infarction, a cerebral infarction etc. In these cases, administering anticoagulants is essential. Anticoagulants are drugs that prevent blood from coagulating, thus avoiding cardiovascular events, which are the leading cause of death in Spain. In recent years, one of the most active fields of research has been the search for the ideal anticoagulant since the ones available today may have side effects and must be administered under strict medical control. "The discovery of this new interaction could be useful in the future to create new generation anticoagulant drugs that improve these aspects and also to fight against the spreading of malaria" concludes Dr. Gutirrez Gallego.


Contact: Marta Calsina
IMIM (Hospital del Mar Medical Research Institute)

Related biology news :

1. Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and Fluorometers to Reach $18.4 bn; Anticoagulants to Reach $12.9 bn; Cell and Tissue Culture Supplies to Reach $5.6 bn
2. Hearty organisms discovered in bitter-cold Antarctic brine
3. Microbial missing link discovered after man impales hand on tree branch
4. Newly discovered effects of vitamin D on cancer
5. Missing link discovered in the defence mechanism of the tuberculosis pathogen
6. New cause of thyroid hormone deficiency discovered
7. Undersea gas leaks off Israels coast are discovered by University of Haifa researchers
8. Sweet new approach discovered to help produce metal casting parts, reduce toxicity
9. 9 colorful and endangered tree-dwelling tarantulas discovered in Brazil
10. New genes discovered for adult BMI levels
11. Living power cables discovered
Post Your Comments:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
(Date:10/27/2015)... Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ... so that they can be quantitatively analyzed with SMI,s ... Germany , October 28-29, 2015. SMI,s Automated Semantic ... eye tracking videos created with SMI,s Eye Tracking ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... Worcester, Mass. (PRWEB) , ... November 24, 2015 ... ... need to maintain healthy metabolism. But unless it is bound to proteins, copper ... Institutes of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
Breaking Biology Technology: